0.35 (-%)
As of Nov 20, 2024
Source:
FibroGen, Inc. is a leading biopharmaceutical company discovering, developing and commercializing a pipeline of first-in-class therapeutics. Our lead product candidate and product are pamrevlumab and roxadustat, respectively.
| Country | United States |
| Headquarters | san francisco, california |
| Phone Number | 415-978-1200 |
| Industry | manufacturing |
| CEO | Thane Wettig |
| Website | www.fibrogen.com |